Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

BACKGROUND: PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiuzhi, Chen, Li, Huang, Binhao, Li, Xiaoguang, Yang, Liu, Hu, Xin, Jiang, Yizhou, Shao, Zhimin, Wang, Zhonghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028839/
https://www.ncbi.nlm.nih.gov/pubmed/33832512
http://dx.doi.org/10.1186/s13046-021-01930-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028839/
https://www.ncbi.nlm.nih.gov/pubmed/33832512
http://dx.doi.org/10.1186/s13046-021-01930-w

Ejemplares similares